ATE154642T1 - Monoklonale antikörper gegen das mikrotubulusassoziierte protein tau. - Google Patents

Monoklonale antikörper gegen das mikrotubulusassoziierte protein tau.

Info

Publication number
ATE154642T1
ATE154642T1 AT92922432T AT92922432T ATE154642T1 AT E154642 T1 ATE154642 T1 AT E154642T1 AT 92922432 T AT92922432 T AT 92922432T AT 92922432 T AT92922432 T AT 92922432T AT E154642 T1 ATE154642 T1 AT E154642T1
Authority
AT
Austria
Prior art keywords
microtubulus
monoclonal antibodies
antibodies against
associated protein
protein tau
Prior art date
Application number
AT92922432T
Other languages
English (en)
Inventor
Marc Mercken
Eva-Maria Mandelkow
Marc Vandermeeren
Eugeen Vanmechelen
De Voorde Andre Van
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Application granted granted Critical
Publication of ATE154642T1 publication Critical patent/ATE154642T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT92922432T 1991-10-25 1992-10-17 Monoklonale antikörper gegen das mikrotubulusassoziierte protein tau. ATE154642T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP91402871 1991-10-25

Publications (1)

Publication Number Publication Date
ATE154642T1 true ATE154642T1 (de) 1997-07-15

Family

ID=8208630

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92922432T ATE154642T1 (de) 1991-10-25 1992-10-17 Monoklonale antikörper gegen das mikrotubulusassoziierte protein tau.

Country Status (10)

Country Link
US (4) US6238892B1 (de)
EP (1) EP0610330B1 (de)
JP (2) JP3909084B2 (de)
AT (1) ATE154642T1 (de)
AU (1) AU662178B2 (de)
CA (1) CA2121599C (de)
DE (1) DE69220503T2 (de)
DK (1) DK0610330T3 (de)
GR (1) GR3024635T3 (de)
WO (1) WO1993008302A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811310A (en) * 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
EP0610330B1 (de) * 1991-10-25 1997-06-18 N.V. Innogenetics S.A. Monoklonale Antikörper gegen das mikrotubulusassoziierte Protein Tau.
JPH06239899A (ja) * 1993-02-12 1994-08-30 Teijin Ltd ヒトタウ蛋白に対する抗体、並びに該抗体を利用する体液中のヒトタウ蛋白の測定方法
PT737208E (pt) 1993-12-21 2006-12-29 Innogenetics Nv Anticorpos monoclonais específicos para phf-tau, hibridomas que os segregam, reconhecimento de antigénios por estes anticorpos e suas aplicações
JPH10506381A (ja) * 1994-07-29 1998-06-23 イノジェネティックス・ナムローゼ・フェンノートシャップ 特定のサブクラスまたは形態のホスホリレーションされたｔａｕのエピトープに特異的なモノクローナル抗体、それらを分泌するハイブリドーマ、これらの抗体の抗原認識およびそれらの応用
JP3671440B2 (ja) 1994-09-16 2005-07-13 株式会社デンソー トルク伝達装置
ATE236386T1 (de) * 1995-11-30 2003-04-15 Chromavision Med Sys Inc Verfahren zur automatischen bildanalyse biologischer proben
US6718053B1 (en) * 1996-11-27 2004-04-06 Chromavision Medical Systems, Inc. Method and apparatus for automated image analysis of biological specimens
US20050084875A1 (en) * 1997-10-24 2005-04-21 University Of Rochester Molecular markers for the diagnosis of Alzheimer's disease
US20020102553A1 (en) * 1997-10-24 2002-08-01 University Of Rochester Molecular markers for the diagnosis of alzheimer's disease
US6797478B1 (en) * 1998-03-05 2004-09-28 University Of Cincinnati Method of detecting axonal damage, from associated disease states using tau monoclonal antibodies
ES2229817T3 (es) * 1998-09-08 2005-04-16 Innogenetics N.V. Uso de la tau como un marcador para la deteccion temprana del daño del sistema nervioso central (cns).
US7146209B2 (en) * 2000-05-08 2006-12-05 Brainsgate, Ltd. Stimulation for treating eye pathologies
AU2002361618A1 (en) * 2001-11-13 2003-05-26 Chromavision Medical Systems, Inc. A system for tracking biological samples
WO2004043218A2 (en) * 2002-11-14 2004-05-27 Brainsgate Ltd. Surgical tools and techniques for stimulation
JP2006500318A (ja) * 2002-04-25 2006-01-05 ブレインスゲート リミテッド 着臭剤の頭内神経への神経興奮性および／または神経抑制性作用を用いてｂｂｂおよび脳循環の特性を加減する方法および装置
US7684859B2 (en) * 2002-04-25 2010-03-23 Brainsgate Ltd. Stimulation of the OTIC ganglion for treating medical conditions
US20050037406A1 (en) * 2002-06-12 2005-02-17 De La Torre-Bueno Jose Methods and apparatus for analysis of a biological specimen
US7272252B2 (en) * 2002-06-12 2007-09-18 Clarient, Inc. Automated system for combining bright field and fluorescent microscopy
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US20040202357A1 (en) 2003-04-11 2004-10-14 Perz Cynthia B. Silhouette image acquisition
WO2005080986A1 (en) * 2004-02-18 2005-09-01 University Of Iowa Research Foundation Antibodies to phosphorylated tau, methods of making and methods of use
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US8010189B2 (en) * 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
US7653260B2 (en) * 2004-06-17 2010-01-26 Carl Zeis MicroImaging GmbH System and method of registering field of view
US8582924B2 (en) * 2004-06-30 2013-11-12 Carl Zeiss Microimaging Gmbh Data structure of an image storage and retrieval system
WO2006021957A2 (en) * 2004-08-23 2006-03-02 Brainsgate Ltd. Concurrent bilateral spg modulation
US20070031043A1 (en) * 2005-08-02 2007-02-08 Perz Cynthia B System for and method of intelligently directed segmentation analysis for automated microscope systems
PT1954718E (pt) 2005-11-30 2014-12-16 Abbvie Inc Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US20090210026A1 (en) * 2006-08-17 2009-08-20 Brainsgate Ltd. Spg stimulation for enhancing neurogenesis and brain metabolism
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US7860569B2 (en) 2007-10-18 2010-12-28 Brainsgate, Ltd. Long-term SPG stimulation therapy for prevention of vascular dementia
AU2009218872B2 (en) 2008-02-29 2015-01-15 Agilent Technologies, Inc. Systems and methods for tracking and providing workflow information
WO2010144711A2 (en) 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
WO2011045166A1 (en) * 2009-09-24 2011-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Fkbp52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction
WO2011053565A2 (en) * 2009-10-29 2011-05-05 Biomedical Sciences Research Centre "Alexander Fleming" Compositions and methods for detecting a tauopathy
WO2011062782A2 (en) * 2009-11-17 2011-05-26 Servicios Cientificos Neuroinnovation Limitada Innovative blood platelets biomarker for early diagnosis of alzheimer's disease
MX360403B (es) 2010-04-15 2018-10-31 Abbvie Inc Proteinas de union a amiloide beta.
EP2603524A1 (de) 2010-08-14 2013-06-19 AbbVie Inc. Amyloid-beta-bindende proteine
JP2014503178A (ja) 2010-10-11 2014-02-13 バイオジェン アイデック インターナショナル ニューロサイエンス ゲーエムベーハー ヒト抗タウ抗体
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
CA3234629A1 (en) 2011-12-20 2013-06-27 Janssen Biotech, Inc. Anti-phf-tau antibodies and their uses
SG11201408626YA (en) 2012-07-03 2015-03-30 Univ Washington Antibodies to tau
JP6290212B2 (ja) * 2012-08-16 2018-03-07 アイピエリアン，インコーポレイティド タウオパチーの処置方法
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
LT2935326T (lt) * 2012-12-21 2020-12-10 Biogen Ma Inc. Žmogaus antikūnai prieš tau baltymą
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
US9675796B2 (en) 2013-11-10 2017-06-13 Brainsgate Ltd. Implant and delivery system for neural stimulator
CN105939722A (zh) 2014-02-14 2016-09-14 伊皮埃里安股份有限公司 Tau肽，抗Tau抗体，及其使用方法
TWI734975B (zh) 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
DE102014013571A1 (de) 2014-09-18 2016-03-24 Aj Roboscreen Gmbh Monoklonaler Antikörper gegen humanes TAU-Protein
EP3093043B1 (de) 2015-05-13 2018-11-14 Brainsgate Ltd. Implantat und abgabesystem für nervenstimulator
TN2017000543A1 (en) 2015-07-06 2019-04-12 Ucb Biopharma Sprl Tau-binding antibodies
MX2019009817A (es) 2017-02-17 2019-11-21 Denali Therapeutics Inc Anticuerpos anti-tau y metodos de uso de los mismos.
JOP20180021A1 (ar) 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
WO2019118906A2 (en) 2017-12-14 2019-06-20 University Of Florida Research Foundation Monoclonal antibodies targeting phf1 and at8 epitopes of human tau protein
US20240101654A1 (en) 2020-12-29 2024-03-28 Neurimmune Ag Human anti-tau antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811310A (en) * 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
US5733734A (en) * 1991-08-14 1998-03-31 The Trustees Of The University Of Pennsylvania Method of screening for Alzheimer's disease or disease associated with the accumulation of paired helical filaments
EP0610330B1 (de) * 1991-10-25 1997-06-18 N.V. Innogenetics S.A. Monoklonale Antikörper gegen das mikrotubulusassoziierte Protein Tau.
DE69318420T2 (de) * 1992-12-14 1999-01-28 Naamloze Vennootschap Innogenetics S.A., Gent Monoklonale antikörper gegen das mikrotubulusassoziierte tauprotein,hybridomen, die diese antikörper sezernieren, antigenerkennung durch diese monoklonalen antikörper und deren verwendung
PT737208E (pt) * 1993-12-21 2006-12-29 Innogenetics Nv Anticorpos monoclonais específicos para phf-tau, hibridomas que os segregam, reconhecimento de antigénios por estes anticorpos e suas aplicações

Also Published As

Publication number Publication date
AU662178B2 (en) 1995-08-24
US20110143443A9 (en) 2011-06-16
DE69220503T2 (de) 1998-02-05
JP2004043487A (ja) 2004-02-12
JPH07502888A (ja) 1995-03-30
US20060008853A1 (en) 2006-01-12
CA2121599C (en) 2007-04-10
US6238892B1 (en) 2001-05-29
US20010018191A1 (en) 2001-08-30
EP0610330A1 (de) 1994-08-17
DE69220503D1 (de) 1997-07-24
GR3024635T3 (en) 1997-12-31
DK0610330T3 (da) 1998-01-26
US6900293B2 (en) 2005-05-31
EP0610330B1 (de) 1997-06-18
US8163873B2 (en) 2012-04-24
CA2121599A1 (en) 1993-04-29
US20090137051A1 (en) 2009-05-28
WO1993008302A1 (en) 1993-04-29
JP3909084B2 (ja) 2007-04-25
AU2800292A (en) 1993-05-21

Similar Documents

Publication Publication Date Title
ATE154642T1 (de) Monoklonale antikörper gegen das mikrotubulusassoziierte protein tau.
ATE165866T1 (de) Monoklonale antikörper gegen das mikrotubulusassoziierte tauprotein,hybridomen, die diese antikörper sezernieren, antigenerkennung durch diese monoklonalen antikörper und deren verwendung
EA200700083A1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их применения
EP0394946A3 (de) Menschlicher monoklonaler Antikörper, seine Herstellung und seine Verwendung
ATE133338T1 (de) Antikörper gegen a4 amyloidpeptid
EP0444856A3 (en) Diagnostic assay for alzheimer's disease
ATE159300T1 (de) Monoklonale antikörper gegen menschliches ige
EP0584715A3 (de) Gewinnung und Kultivierung transformierter Zellen und Herstellung gegen sie gerichteter Antikörper.
DE69333076D1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
FI900230A0 (fi) Anti-idiotypa antikroppar mot antikroppar mot antigener med hoeg molekylvikt associerade till human melanoma.
NO972522L (no) Monoklonale antistoffer med immunoundertrykkende aktivitet
AU5809290A (en) Monoclonal antibodies involved in alzheimer's disease, hybridomas secreting these monoclonal antibodies, antigen recognized by these antibodies, and their application
ATE137674T1 (de) Von mca 16-88 erkanntes antigen
KR890016165A (ko) 수도모나스 아에루기노사(Pseudomonas aeruginosa)에 대한 모노클로날 항체, 이의 제조방법 및 용도
ATE138200T1 (de) Das von mca-28a32 erkannte antigen
DE3784364D1 (de) Tumorassoziiertes antigen.
CA2151945A1 (en) Assay and treatment for demyelinating diseases such as multiple sclerosis
DK182188A (da) Humant tumorassocieret antigen
TH30771A (th) แอนติ- Fas รีคอมบีแนนท์ แอนติบอดี และ DNA ของส่วนดังกล่าว

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification